Immunotherapy-Based Approaches in Cancer Management

Sonal Bhingare[1]*, Puja G. Vyawhare[2], Kanvesh Chaudhari[1], Darshan Borle[1], Aditi Bhagwat[1], Rupali R. Tasgaonkar[3]

[1] Final Year B.Pharm Student, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India

[2] Associate Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India

[3] Principal & Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Bhivpuri Road, Maharashtra, India

Corresponding author: Sonal Bhingare

Abstract—**Cancer immunotherapy represents a major advancement in oncology by leveraging the body's immune system to selectively target and eliminate malignant cells. Unlike traditional therapies that directly destroy rapidly dividing cells, immunotherapy enhances immune recognition and activation, thereby offering improved specificity and reduced systemic toxicity. Key immunotherapeutic approaches include immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and adoptive cell therapies, which may be administered as monotherapies or in combination with conventional treatments. Recent innovations have introduced next-generation strategies such as chimeric antigen receptor T-cell therapy, personalized neoantigen vaccines, oncolytic virus therapy, microbiome-modulating interventions, and mRNA-based platforms. These advances aim to enhance therapeutic precision, overcome resistance, and reduce adverse effects. Clinically, immunotherapy has demonstrated significant efficacy in multiple malignancies, including melanoma, lung cancer, lymphoma, and renal cell carcinoma, often resulting in durable responses and improved survival. Despite these successes, challenges such as heterogeneous patient responses, immune-related toxicities, high treatment costs, and acquired resistance remain. Ongoing research focuses on biomarker discovery, mechanistic insights, and rational combination strategies to optimize clinical outcomes. Overall, cancer immunotherapy continues to reshape modern oncology, offering promising opportunities for personalized, targeted, and durable cancer treatment.**

Keywords—**Cancer immunotherapy; immune checkpoint inhibitors; CAR-T cell therapy; oncology; targeted immunotherapy**


Fig. 1 Graphical Abstract

I. INTRODUCTION

Cancer is characterized by the uncontrolled proliferation of abnormal cells resulting from the disruption of normal cellular regulatory mechanisms. These malignant cells possess the ability to invade surrounding tissues and metastasize to distant organs through the circulatory and lymphatic systems, contributing significantly to cancer-related morbidity and mortality. Despite major advances in conventional treatment strategies such as surgery, chemotherapy, and radiotherapy, many cancers remain difficult to cure, particularly in advanced or metastatic stages. Moreover, these treatments are often associated with significant adverse effects, including systemic toxicity, immunosuppression, and reduced quality of life.

Immunotherapy represents a paradigm shift in cancer treatment by utilizing the body's own immune system to recognize and eliminate tumor cells. The immune system plays a critical role in maintaining cellular homeostasis by identifying and destroying abnormal or foreign cells. However, cancer cells can evade immune surveillance through various mechanisms, including immune checkpoint activation, antigen loss, and the creation of an immunosuppressive tumor microenvironment. Immunotherapeutic interventions are designed to overcome these escape mechanisms, thereby restoring effective anti-tumor immune responses.

Immunotherapy is a type of cancer treatment that uses our own immune system to fight cancer. The immune system is our body's natural defense system. It helps protect us from infections, viruses, and diseases. It includes white blood cells, antibodies, and other components that work together to detect and destroy harmful substances. Cancer cells are tricky because they can hide from the immune system or produce signals that stop immune cells from attacking them. Immunotherapy helps the immune system to identify these hidden cancer cells and kill them. In simple words, it boosts the power of your natural immune system to recognize and destroy cancer cells effectively.

The concept of immunotherapy is not completely new. In the late 19th century, a doctor named William Coley noticed that some cancer patients improved after they got bacterial infections. He tried using bacteria to stimulate the immune system to fight cancer. This was one of the first examples of immunotherapy. Later, in the 20th century, scientists discovered more about how the immune system works, including T-cells, antigens, and immune checkpoints. Major progress happened in the last 30 years. Scientists developed new drugs like checkpoint inhibitors (e.g., nivolumab, pembrolizumab), CAR T-cell therapy, monoclonal antibodies, and cancer vaccines. These treatments have shown great results in certain cancers like melanoma, lung cancer, and blood cancers. Today, immunotherapy is one of the most exciting and fast-growing areas in cancer research.


Fig.1: Drug Herbal Adjuvant Formulation

Although the conceptual foundation of cancer immunotherapy dates back to the late nineteenth century with early observations by William Coley, substantial progress has been achieved over the past few decades owing to advances in molecular biology and immunology. The development of immune checkpoint inhibitors, adoptive T-cell therapies, monoclonal antibodies, and therapeutic cancer vaccines has revolutionized cancer care, particularly in malignancies such as melanoma, lung cancer, and hematological cancers. As a result, immunotherapy has become one of the most rapidly evolving and impactful areas of oncology research.

II. MECHANISM OF ACTION OF CANCER IMMUNOTHERAPY

Cancer immunotherapy functions by enhancing or restoring the ability of the immune system to recognize and eliminate malignant cells. Under

normal physiological conditions, the immune system continuously monitors the body through immune surveillance, identifying and destroying abnormal or mutated cells. However, cancer cells originate from normal host cells and often develop sophisticated mechanisms to evade immune detection, allowing uncontrolled growth and disease progression. Immunotherapy intervenes in this process by reactivating immune responses or supplying immune components that can specifically target cancer cells. The principal mechanisms of action are summarized below.

2.1 Immune Checkpoint Inhibition

T lymphocytes play a central role in antitumor immunity. Their activity is regulated by immune checkpoints such as programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), which normally function to prevent excessive immune activation. Cancer cells exploit these pathways by overexpressing checkpoint ligands, effectively switching off T-cell responses. Immune checkpoint inhibitors block these inhibitory signals, thereby restoring T-cell activation and enabling effective destruction of tumor cells.

2.2 Monoclonal Antibody–Mediated Targeting

Monoclonal antibodies are engineered to bind selectively to tumor-associated antigens expressed on cancer cells. Upon binding, these antibodies can directly inhibit tumor growth, trigger antibody-dependent cellular cytotoxicity (ADCC), or activate the complement system. In addition, some monoclonal antibodies act as immune modulators by targeting immune checkpoints or cytokine receptors, further enhancing antitumor immune responses.

2.3 Cancer Vaccines

Cancer vaccines stimulate the immune system by presenting tumor-specific or tumor-associated antigens to antigen-presenting cells. This process primes cytotoxic T lymphocytes and memory immune cells, enabling long-term immune surveillance and reducing the risk of cancer recurrence. Unlike preventive vaccines, cancer vaccines are primarily therapeutic and are designed to enhance existing immune responses against established tumors.

2.4 Adoptive Cell Transfer and CAR-T Cell Therapy

Adoptive cell transfer involves the isolation, expansion, and reinfusion of immune cells with antitumor activity. In chimeric antigen receptor T-cell (CAR-T) therapy, patient-derived T cells are genetically modified to express synthetic receptors that recognize specific tumor antigens. Once reinfused, these engineered T cells directly bind to cancer cells and induce targeted cytotoxicity, independent of major histocompatibility complex (MHC) presentation.

2.5 Immune System Modulation

Certain immunotherapeutic agents, including cytokines such as interleukins and interferons, enhance immune cell proliferation, activation, and signaling. These agents amplify immune responses within the tumor microenvironment, counteracting immunosuppressive factors produced by cancer cells and supporting sustained antitumor activity.

2.6 Overall Immunological Impact

Collectively, these mechanisms aim to overcome tumor-induced immune evasion, reinstate immune surveillance, and promote selective destruction of malignant cells while minimizing damage to normal tissues. By targeting both cancer cells and the immunosuppressive tumor microenvironment, immunotherapy provides a highly specific and adaptable approach to cancer treatment.

Causes of Immunotherapy in Cancer Treatment :

1. Cancer hides from immune system : Cancer cells change their shape and signals, so immune cells (like T-cells) can't see or recognize them. That's why the body doesn't attack them.

2. Cancer turns off T-cells : Cancer uses a special trick — it shows a protein called PD- L1, which binds to PD-1 on T-cells. This turns the T-cell OFF, so it stops working.

3. Tumor area becomes weak for immune system : The area around the cancer (tumor) releases chemicals like TGF-β and IL-10. These chemicals make immune cells weak and stop them from working.

III. TUMOR IMMUNE EVASION AND PATHOPHYSIOLOGY

Under normal physiological conditions, immune surveillance mechanisms enable T cells to identify and eliminate abnormal cells. However, cancer cells develop multiple strategies to escape immune recognition. These include alterations in antigen presentation, overexpression of immune checkpoint

ligands such as PD-L1, secretion of immunosuppressive cytokines (e.g., TGF-β and IL-10), recruitment of regulatory immune cells, and induction of T-cell exhaustion. These processes collectively contribute to tumor progression and resistance to immune-mediated destruction. Immunotherapeutic strategies aim to counteract these mechanisms by reactivating exhausted T cells, blocking immunosuppressive signals, and modifying the tumor microenvironment to support effective immune responses.

IV. ADVANCED TECHNIQUES IN CANCER IMMUNOTHERAPY (2025)

Recent technological advances have significantly expanded the scope and effectiveness of cancer immunotherapy. Next-generation CAR-T cell therapies now incorporate dual-target receptors, safety-switch mechanisms, and allogeneic "off-the-shelf" products to improve efficacy and accessibility. Novel immune checkpoint inhibitors targeting emerging checkpoints such as LAG-3 and TIGIT are being developed to enhance therapeutic outcomes.

Personalized neoantigen vaccines, oncolytic virus therapies, bispecific antibodies, cryoimmunotherapy, microbiome-modulating approaches, and mRNA-based platforms represent cutting-edge strategies designed to improve specificity, reduce toxicity, and overcome resistance. Artificial intelligence–driven treatment optimization further supports personalized immunotherapy regimens tailored to individual patient profiles.

V. CLINICAL APPLICATIONS OF CANCER IMMUNOTHERAPY

Immunotherapy has become an integral component of clinical oncology practice. Immune checkpoint inhibitors are now standard treatments for several solid tumors, including non–small cell lung cancer, melanoma, and head and neck cancers. CAR-T cell therapy has demonstrated remarkable efficacy in hematological malignancies such as leukemia, lymphoma, and multiple myeloma. Additionally, immunotherapy is increasingly employed in adjuvant and neoadjuvant settings to improve surgical outcomes and reduce recurrence risk.

VI. ADVANTAGES AND LIMITATIONS

Immunotherapy offers several advantages, including durable immune memory, reduced harm to healthy tissues, and effectiveness in treatment-resistant cancers. However, limitations such as variable patient response, immune-related adverse events, high cost, delayed therapeutic onset, and the potential for acquired resistance continue to pose challenges. Addressing these limitations remains a key focus of ongoing research.

VII. FUTURE PERSPECTIVES

The future of cancer immunotherapy lies in the integration of precision medicine approaches, biomarker-driven patient selection, and rational combination therapies. Advances in mRNA technology, artificial intelligence, and microbiome research are expected to further enhance therapeutic efficacy while reducing toxicity and cost. Continued innovation and global collaboration will be essential to make immunotherapy more accessible and effective across diverse patient populations.

VIII. CONCLUSION

Cancer immunotherapy has fundamentally transformed cancer treatment by leveraging the immune system's capacity to selectively target malignant cells. With the advent of advanced immunotherapeutic modalities such as CAR-T cell therapy, personalized vaccines, and immune modulators, treatment options have expanded significantly. Although challenges related to safety, cost, and resistance persist, continuous scientific progress and technological innovation position immunotherapy as a cornerstone of future oncology care, offering personalized, targeted, and durable treatment solutions.

REFERENCE

[1] Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.

[2] June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.

[3] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.

[4] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668.

[5] Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 2016;14:73.

[6] Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35.

[7] Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: Challenges and opportunities. Stem Cell Res Ther. 2021;12:81.

[8] Houot R, Schultz LM, Marabelle A, Kohrt H. T-cell–based immunotherapy: Adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res. 2015;3(9):911–919.

[9] Zhang M, Liu C, Tu J, et al. Advances in cancer immunotherapy: Historical perspectives, current developments, and future directions. Mol Cancer. 2025;24:136.

[10] Liu C, Yang M, Zhang D, et al. Clinical cancer immunotherapy: Current progress and prospects. Front Immunol. 2022;13:961805.

[11] Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–489.

[12] Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

[13] Ghemrawi R, Abuamer L, Kremesh S, et al. Revolutionizing cancer treatment: Recent advances in immunotherapy. Biomedicines. 2024;12(9):2158.

[14] Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies. Clin Cancer Res. 2016;22(8):1865–1874.

[15] Thakur A, Huang M, Lum LG. Bispecific antibody-based therapeutic approaches in cancer treatment. Cancers (Basel). 2018;11(1):38.

[16] Hou B, Tang Y, Li W, Zeng Q, Chang D. Efficiency of mRNA vaccines for cancer immunotherapy. Front Immunol. 2021;12:669218.

[17] Jiang T, Shi T, Zhang H, et al. Tumor neoantigens: From basic research to clinical applications. J Hematol Oncol. 2019;12(1):93.

[18] Russell SJ, Peng KW. Oncolytic virotherapy: A contest between apples and oranges. Mol Ther. 2018;26(4):943–954.

[19] Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97–111.

[20] Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–723.

[21] Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell. 2018;33(4):581–598.

[22] Li Y, Chen M. Tumor-infiltrating lymphocyte therapy: An emerging cell therapy for cancer. Front Immunol. 2022;13:919010.

[23] Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–1370.

[24] Marcus A, Gowen BG, Thompson TW, et al. Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 2014;122:91–128.

[25] Vanmeerbeek I, Sprooten J, De Ruysscher D, et al. Chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology. 2020;9(1):1703449.

[26] Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(6):394–410.

[27] Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell. 2018;175(2):313–326.

[28] Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–330.

[29] Couzin-Frankel J. Breakthrough of the year 2013: Cancer immunotherapy. Science. 2013;342(6165):1432–1433.

[30] Dougan M, Dranoff G, Dougan SK. Cancer immunotherapy: Beyond checkpoint blockade. Annu Rev Cancer Biol. 2019;3:55–75.